BDSX Biodesix Inc
Price (delayed)
$0.6277
Market cap
$91.63M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.33
Enterprise value
$127.36M
Biodesix, Inc. operates as a biotechnology company. The Company offers non-small cell lung cancer pretreatment serum tests and laboratory testing. Biodesix provides diagnostic tools and equipment for blood and tissue
Highlights
The company's gross profit has surged by 55% YoY and by 9% QoQ
BDSX's EPS is up by 48% year-on-year and by 13% since the previous quarter
Biodesix's quick ratio has soared by 138% YoY but it has decreased by 20% from the previous quarter
The equity has declined by 25% since the previous quarter
BDSX's debt is up by 2.1% YoY
Key stats
What are the main financial stats of BDSX
Market
Valuations
Earnings
Shares outstanding
145.98M
Market cap
$91.63M
Enterprise value
$127.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.37
Price to sales (P/S)
1.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.79
Revenue
$71.32M
Gross profit
$55.75M
Operating income
-$34.5M
Net income
-$42.93M
EBIT
-$34.67M
EBITDA
-$28.9M
Free cash flow
-$52.09M
Per share
Balance sheet
Liquidity
EPS
-$0.33
EPS diluted
-$0.33
Free cash flow per share
-$0.4
Book value per share
$0.14
Revenue per share
$0.55
TBVPS
$0.59
Total assets
$97.24M
Total liabilities
$76.37M
Debt
$61.98M
Equity
$20.88M
Working capital
$25.17M
Debt to equity
2.97
Current ratio
2.76
Quick ratio
2.43
Net debt/EBITDA
-1.24
Margins
Efficiency
Dividend
EBITDA margin
-40.5%
Gross margin
78.2%
Net margin
-60.2%
Operating margin
-48.4%
Return on assets
-42.6%
Return on equity
-216%
Return on invested capital
-36.9%
Return on capital employed
-41.8%
Return on sales
-48.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BDSX stock price
How has the Biodesix stock price performed over time
Intraday
3.56%
1 week
-16.53%
1 month
-20.84%
1 year
-57.87%
YTD
-58.97%
QTD
0.4%
Financial performance
How have Biodesix's revenue and profit performed over time
Revenue
$71.32M
Gross profit
$55.75M
Operating income
-$34.5M
Net income
-$42.93M
Gross margin
78.2%
Net margin
-60.2%
The company's gross profit has surged by 55% YoY and by 9% QoQ
Biodesix's revenue has increased by 45% YoY and by 9% QoQ
The operating margin has increased by 43% year-on-year and by 9% since the previous quarter
BDSX's net margin is up by 43% YoY and by 10% QoQ
Growth
What is Biodesix's growth rate over time
Valuation
What is Biodesix stock price valuation
P/E
N/A
P/B
4.37
P/S
1.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.79
BDSX's EPS is up by 48% year-on-year and by 13% since the previous quarter
The equity has declined by 25% since the previous quarter
The price to sales (P/S) is 65% lower than the 5-year quarterly average of 3.1 and 65% lower than the last 4 quarters average of 3.1
Biodesix's revenue has increased by 45% YoY and by 9% QoQ
Efficiency
How efficient is Biodesix business performance
The ROE has soared by 99% YoY and by 22% QoQ
BDSX's ROIC is up by 48% YoY and by 6% QoQ
BDSX's ROS is up by 44% year-on-year and by 9% since the previous quarter
BDSX's return on assets is up by 30% year-on-year
Dividends
What is BDSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BDSX.
Financial health
How did Biodesix financials performed over time
The company's total assets is 27% higher than its total liabilities
Biodesix's quick ratio has soared by 138% YoY but it has decreased by 20% from the previous quarter
The company's current ratio has surged by 132% YoY but it fell by 19% QoQ
BDSX's debt is 197% higher than its equity
The debt to equity has dropped by 78% year-on-year but it is up by 34% since the previous quarter
The equity has declined by 25% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.